{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032644","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2026-08-13T12:01:03+00:00","discovered_at":"2026-08-13T12:05:08.300287+00:00","generated_at":"2026-08-13T12:05:17.073822+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Grace Therapeutics Q1 net loss $15.8M, $13.5M IPR&D impairment","bullets":["Net loss $15.8M ($0.91/share) vs $3.4M ($0.21) YoY; includes $13.5M impairment of GTx-101/102 IPR&D.","Cash $22.2M as of Aug 11, 2026; runway through end of 2028; $10M private placement announced.","FDA Type A meeting minutes received; CRL items are CMC/non-clinical, no clinical safety/efficacy issues.","Dual-source manufacturing: tech transfer to second U.S. CMO underway; NDA resubmission timing depends on site readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032644","json":"https://secwatch.observer/filing/0001140361-26-032644.json","markdown":"https://secwatch.observer/filing/0001140361-26-032644.md","text":"https://secwatch.observer/filing/0001140361-26-032644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/0001140361-26-032644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:05:17.073822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}